In contrast to the many cell and gene therapy accelerated approvals that have been criticized for lengthy confirmatory trial timelines, Adaptimmune Therapeutics plc is gearing up for a relatively quick bid for full approval of its newly cleared melanoma-associated antigen A4 (MAGE-A4)-directed autologous T-cell immunotherapy Teclera (afamitresgene autoleucel).
Key Takeaways
-
Adaptimmune’s MAGE-A4 directed autologous T-cell therapy Teclera earned accelerated approval 1 August for chemotherapy-experienced synovial sarcoma patients who have specific HLA types and whose tumors express the MAGE-A4 antigen
Confirmatory evidence is expected to be submitted to the FDA “next year to complete that obligation and convert this application to regular approval,”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?